Organon & Co (OGN)
18.07
-0.71
(-3.78%)
USD |
NYSE |
Nov 01, 16:00
18.02
-0.05
(-0.28%)
After-Hours: 20:00
Organon Total Liabilities (Quarterly): 12.26B for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 12.26B |
| June 30, 2024 | 12.01B |
| March 31, 2024 | 11.84B |
| December 31, 2023 | 12.13B |
| September 30, 2023 | 11.60B |
| June 30, 2023 | 11.53B |
| March 31, 2023 | 11.50B |
| December 31, 2022 | 11.85B |
| Date | Value |
|---|---|
| September 30, 2022 | 11.50B |
| June 30, 2022 | 11.75B |
| March 31, 2022 | 11.85B |
| December 31, 2021 | 12.19B |
| September 30, 2021 | 12.95B |
| June 30, 2021 | 12.84B |
| March 31, 2021 | 4.92B |
| December 31, 2020 | 4.623B |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
4.623B
Minimum
Dec 2020
12.95B
Maximum
Sep 2021
11.08B
Average
11.84B
Median
Total Liabilities (Quarterly) Benchmarks
| Eli Lilly and Co | 61.29B |
| Biomarin Pharmaceutical Inc | 1.438B |
| Cassava Sciences Inc | 54.59M |
| Ligand Pharmaceuticals Inc | 91.21M |
| TG Therapeutics Inc | 223.64M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 12.75B |
| Shareholders Equity (Quarterly) | 493.00M |
| Debt to Equity Ratio | 17.75 |
| Current Ratio | 1.705 |
| Net Debt Paydown Yield | -0.08% |